Clinical Trials Logo

Recurrent Urethral Cancer clinical trials

View clinical trials related to Recurrent Urethral Cancer.

Filter by:

NCT ID: NCT02122172 Recruiting - Clinical trials for Stage IV Bladder Cancer

Afatinib in Advanced Refractory Urothelial Cancer

Start date: October 30, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well afatinib dimaleate works in treating patients with urothelial cancer that cannot be removed surgically and has grown after treatment with standard first-line chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause some of the cells to die.

NCT ID: NCT01846520 Recruiting - Clinical trials for Psychosocial Effects of Cancer and Its Treatment

Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers

Start date: October 2013
Phase: N/A
Study type: Interventional

This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers. Education and telephone counseling may reduce stress and improve the well-being and quality of life of caregivers of cancer patients.

NCT ID: NCT01639521 Withdrawn - Clinical trials for Transitional Cell Carcinoma of the Bladder

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Start date: May 2013
Phase: Phase 2
Study type: Interventional

This study is about two chemotherapy study drug combinations (regimens) that are used for urothelial (bladder or upper urinary tract) cancer. Both study drug regimens, gemcitabine (gemcitabine hydrochloride) plus cisplatin, and high-dose-intensity MVAC (methotrexate, vinblastine, doxorubicin plus cisplatin), are standard chemotherapy regimens. Both regimens are used to treat people with urothelial cancer that has spread to other organs. Both study drug regimens have been proven to be effective in lowering the risk of the cancer coming back, but it is not known which regimen is the best. This study hopes to learn whether there is a difference in the effectiveness and side effects of these two study drug regimens when they are given to people who have had their urothelial cancer completely removed.

NCT ID: NCT00478361 Completed - Clinical trials for Stage IV Bladder Cancer

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Start date: April 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving gemcitabine, paclitaxel, and doxorubicin together with pegfilgrastim works in treating patients with metastatic or unresectable bladder cancer or urinary tract cancer and kidney dysfunction. Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Colony stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. Giving combination chemotherapy together with pegfilgrastim may kill more tumor cells. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.

NCT ID: NCT00471536 Completed - Clinical trials for Stage IV Bladder Cancer

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Start date: August 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00407485 Completed - Clinical trials for Stage IV Bladder Cancer

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor.

NCT ID: NCT00112905 Terminated - Clinical trials for Stage IV Bladder Cancer

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00072150 Completed - Clinical trials for Stage IV Bladder Cancer

Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. This phase II trial is studying how well bortezomib works in treating patients with advanced transitional cell carcinoma of the urothelium.

NCT ID: NCT00021099 Completed - Clinical trials for Stage IV Bladder Cancer

Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer

Start date: June 2001
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of ixabepilone in treating patients who have progressive or metastatic urinary tract cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

NCT ID: NCT00009867 Completed - Clinical trials for Transitional Cell Carcinoma of the Bladder

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Start date: December 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent cancer of the bladder or urinary tract. Arsenic trioxide may kill tumor cells that have become resistant to standard chemotherapy regimens.